HR-5376-117
Became Public Law No: 117-169.
What it does
The Inflation Reduction Act, enacted in 2022, does three major things: (1) it creates and extends dozens of tax credits for clean energy production, electric vehicles, and energy-efficient homes and buildings while funding conservation and rural energy programs; (2) it allows Medicare to negotiate prescription drug prices for the first time, caps Medicare out-of-pocket drug costs at $2,000 annually, and limits insulin copays at $35 per month for Medicare enrollees; and (3) it raises federal revenue through a 15% corporate alternative minimum tax on companies with over $1 billion in average annual profits, a 1% excise tax on corporate stock buybacks, and roughly $80 billion in new IRS funding. It also extends expanded Affordable Care Act premium tax credits through 2025.
Who benefits
Medicare enrollees, particularly those with high drug costs or diabetes, who face lower out-of-pocket costs. Seniors broadly, through the $2,000 annual out-of-pocket cap on Part D drug spending. Lower- and middle-income households purchasing electric vehicles, home energy upgrades, or rooftop solar. Manufacturers of clean energy equipment, electric vehicles, and batteries. Rural communities and agricultural producers receiving renewable energy grants and loans. Workers in clean energy construction and manufacturing, especially those in union-scale prevailing wage jobs. Communities near coal mines or fossil fuel facilities designated as "energy communities" that receive bonus tax credits for new projects. Low-income communities receiving targeted solar and wind capacity allocations. Small businesses under five years old that gain expanded research tax credit offsets. Taxpayers who use the new free IRS direct e-file system. The Black Lung Disability Trust Fund, which receives a permanent excise tax increase on coal.
Who is hurt
Pharmaceutical manufacturers, who face mandatory price negotiations and inflation-based rebate requirements that may reduce revenue on high-spending Medicare drugs. Pharmacy benefit managers and insurers, who absorb restructured Part D cost-sharing. Fossil fuel producers, who face a reinstated Superfund excise tax on crude oil and petroleum products. Large corporations with over $1 billion in profits, subject to the new 15% minimum tax. Publicly traded companies that conduct stock buybacks, subject to the new 1% excise tax. Shareholders of those companies, who may see reduced buyback activity. High-income earners above $150,000 (single) or $300,000 (married) who are excluded from the electric vehicle tax credit. Buyers of EVs priced above $55,000–$80,000, who are ineligible for the credit. Coal-dependent utilities and their ratepayers in regions where compliance costs may rise. Workers in fossil fuel industries facing long-term structural decline accelerated by clean energy incentives. Tax professionals and tax preparation companies (e.g., H&R Block, TurboTax) who may lose business to the new free IRS direct e-file system.
Supporters argue
Supporters argue the law addresses three simultaneous crises with a single, fiscally responsible package. On climate, they contend it represents the largest climate investment in U.S. history — the Rhodium Group and Princeton's REPEAT Project projected it would reduce U.S. greenhouse gas emissions by roughly 40% below 2005 levels by 2030, compared to roughly 26% without it. On drug costs, they argue that Medicare — which covers over 65 million Americans — has been legally prohibited from negotiating drug prices since 2003, and that the law corrects a structural market failure: the U.S. pays two to four times more for the same drugs than peer nations. On fiscal impact, they cite CBO's estimate that the law reduces the federal deficit by approximately $238 billion over ten years, meaning it funds its spending through new revenues rather than borrowing.
Opponents argue
Opponents argue the law's tax and regulatory provisions impose real economic costs that its projections understate. On the corporate minimum tax, they contend it disrupts longstanding depreciation and investment incentives, potentially reducing capital formation — the National Association of Manufacturers estimated it could cost the sector tens of billions in effective tax increases. On drug pricing, they argue that government-set price ceilings reduce the financial return on pharmaceutical research and development; the Congressional Budget Office itself projected the negotiation provisions would result in 15 fewer new drugs entering the market over the next decade. On energy, they contend the law's hundreds of billions in targeted tax credits represent industrial policy that picks winners and losers, distorts energy markets, and may not survive shifts in political will or future budget reconciliation processes.
Constitutional context
The law's drug price negotiation provisions raise potential Fifth Amendment Takings Clause questions: manufacturers who refuse to negotiate face escalating excise taxes that can reach up to 95% of a drug's gross sales, which some legal scholars argue functions as a coercive taking of property rather than a voluntary negotiation. The law's extensive delegation of rulemaking authority to CMS and Treasury agencies also implicates the major questions doctrine established in West Virginia v. EPA (2022) and the post-Chevron independent judicial review standard of Loper Bright v. Raimondo (2024), as courts will independently assess whether Congress provided sufficiently clear authorization for agency rules of vast economic significance.
Checks and balances
The executive branch — primarily CMS, Treasury, and USDA — gains significant new rulemaking and negotiating authority; Congress retains oversight through appropriations and sunset provisions on several credits, and federal courts may review agency actions under the heightened post-Loper Bright standard without deferring to agency interpretations.
Historical precedent
The Medicare Modernization Act of 2003 created Medicare Part D but explicitly prohibited Medicare from negotiating drug prices; the IRA reverses that prohibition for the first time, making it the first federal law to authorize direct Medicare drug price negotiation in the program's history.